In recent years, numerous studies have found that pharmacological and genetic inhibition of E2F1 significantly inhibited tumor growth in CRC and E2F1 has also been revealed to participate in the metastasis and chemoresistance of CRC [13–15]. This evidence concerns the gene E2F1 and colorectal carcinoma.